Biotechnology Assets Stock

Biotechnology Assets Financial Leverage

The Financial Leverage (Equity Multiplier) of Biotechnology Assets (BST.MC) as of Aug 8, 2026 is 2.20. In the previous year, Financial Leverage (Equity Multiplier) was 2.24 — a change of -1.81% (lower).

Financial Leverage

2.20

YoY

-1.81%

Last updated:

Financial Leverage (Equity Multiplier) of Biotechnology Assets is 2026 2.20 . Financial Leverage (Equity Multiplier) of Biotechnology Assets was 2025 2.24 . It decreases by -1.81% lower compared to the previous year.
Access this data via the Eulerpool API

Biotechnology Assets Stock analysis

What does Biotechnology Assets do? ADL Bionatur Solutions SA is a Swiss company specializing in the development and production of natural ingredients for the food, cosmetics, and pharmaceutical industries. The company was founded in 2000 and has since had an impressive success story. ADL Bionatur Solutions SA's business model is based on the use of plants and microorganisms to extract high-quality natural active ingredients. The company employs environmentally friendly methods and sustainable production practices that meet the needs of society and nature alike. One of ADL Bionatur Solutions SA's main sectors is the production of natural flavors and colorants for the food industry. Depending on customer preferences, color pigments are extracted from fruits, vegetables, or other plants to color food products with natural ingredients. Natural flavors are also isolated using plant extracts and other natural sources. These products are particularly sought after because they are not only healthier than synthetic alternatives but also provide consumers with a better feeling. Another significant sector of ADL Bionatur Solutions SA is the development of cosmetics based on natural ingredients. For example, extracts from algae, flowers, or herbs are used to create skincare products that are gentle on the skin while still being highly effective. Products targeting signs of aging or acne are also based on natural ingredients from ADL Bionatur Solutions SA. In addition to these two main sectors, ADL Bionatur Solutions SA also offers products for the pharmaceutical industry. The company focuses on developing active ingredients based on natural substances that can be used to treat various diseases. Sustainability is also a key focus here, as naturally derived active ingredients are not only healthier but also have a higher biological availability. In addition to these main sectors, ADL Bionatur Solutions SA provides consulting services to customers. This includes the development of tailored natural solutions and support for product certification according to the highest international standards. Overall, in recent years, ADL Bionatur Solutions SA has become one of the world's leading companies in the field of natural ingredients. With a wide portfolio of products and services and a strong focus on sustainability and environmental compatibility, the company is well-positioned to benefit from the ongoing trend towards natural and healthier products. Biotechnology Assets is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotechnology Assets stock

Financial Leverage (Equity Multiplier) of Biotechnology Assets is 2.20 in 2026.

Financial Leverage (Equity Multiplier) of Biotechnology Assets changed from 2.24 to 2.20, representing a -1.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Biotechnology Assets since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Biotechnology Assets with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Biotechnology Assets

All Key Metrics — Biotechnology Assets